BioSpace News Archive

Concordia today announced that it has taken a further step in its previously announced efforts to realign its capital structure by commencing a court proceeding under the CBCA.

This IMPD has been submitted through the EMA clinical trial portal for approval prior to opening of clinical centers in France.

Adults likely do not develop ADHD, according to new research by FIU clinical psychologist Margaret Sibley.

RenovaCare announced the closing of its previously announced registered direct offering of 915,000 shares of its common stock at a an offering price of $2.50 per share and its concurrent private placement of common stock purchase warrants (the “Warrants” to purchase 915,000 shares of common stock.

Veracyte, Inc. announced that data presented at the 87th Annual Meeting of the American Thyroid Association (ATA) being held October 18-22 in Victoria, BC, Canada.

Shionogi announced it will present positive efficacy and safety results from a global Phase 3 study (L-PLUS 2) of lusutrombopag (S-888711), an investigational, once-daily, orally administered, small molecule thrombopoietin (TPO) receptor agonist, at the 2017 American Association for the Study of Liver Diseases (AASLD) Liver Meeting to be held October 20-24 in Washington, D.C.

The company has scheduled a conference call for 8:30 AM ET the same day to discuss the results and to give an update on its clinical and development activities.

The EMA has designated ofranergene obadenovec (VB-111) as an ‘orphan medicinal product’ for the treatment of ovarian cancer.

SeaSpine’s management team will host a corresponding conference call beginning at 1:30pm PT/4:30pm ET to discuss the financial results and recent business developments.

Results from nearly 32,000 samples analyzed in this study indicate that genomic alterations decrease in frequency and severity from conception through development into childhood.